Loading
Basal-like 2 is a subtype of triple-negative breast cancer that shares the basal identity of basal-like 1 but is driven more by growth-factor signalling than by DNA damage, and it responded worst to standard chemotherapy before surgery in the studies that defined it, with pathological complete response in about one in five patients or fewer.
In the six-subtype classification, BL2 tumours showed enrichment for growth factor signalling (EGF, NGF, MET, Wnt and IGF1R pathways), glycolysis and gluconeogenesis, and expressed myoepithelial markers, alongside the cell-cycle signature they share with BL1 (Lehmann 2011). Their chemotherapy response is the poorest of the intrinsic subtypes: 18 percent pathological complete response across five neoadjuvant datasets (Lehmann 2016) and 0 percent in the 130-patient MD Anderson series (Masuda 2013). No BL2-specific treatment exists; the growth-factor dependence is the rationale for trials of EGFR, MET and PI3K-pathway agents in triple-negative disease, none of which is approved.
A research classification by gene expression (Lehmann 2011, refined 2016), not a test the NHS runs; treatment follows the triple-negative rows on the parent page.
One of the four tumour-intrinsic triple-negative subtypes in the refined Lehmann classification; a research category.
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
Same organ: Triple-negative breast cancer (TNBC), Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, HER2-positive breast cancer with brain metastases, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Basal-like 1 triple-negative breast cancer (BL1), Mesenchymal triple-negative breast cancer (M), Mesenchymal stem-like triple-negative breast cancer (MSL), Luminal androgen receptor triple-negative breast cancer (LAR), Immunomodulatory triple-negative breast cancer (IM), Metaplastic breast carcinoma, Carcinoma with medullary pattern (medullary breast cancer), Adenoid cystic carcinoma of the breast, Apocrine carcinoma of the breast, Secretory carcinoma of the breast, BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, Invasive breast carcinoma of no special type (invasive ductal carcinoma), Tubular carcinoma of the breast, Mucinous carcinoma of the breast, Papillary carcinomas of the breast (encapsulated, solid and invasive papillary), Invasive cribriform carcinoma of the breast, Invasive breast carcinoma with medullary pattern (medullary carcinoma), Invasive micropapillary carcinoma of the breast, Neuroendocrine neoplasms of the breast, Lobular carcinoma in situ (LCIS)
As for triple-negative disease (KEYNOTE-522 regimen); the low pathological complete response rate in this subtype is a research observation, not a reason to change treatment.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Basal-like 2 triple-negative breast cancer" OR ABSTRACT:"Basal-like 2 triple-negative breast cancer" OR TITLE:"BL2" OR ABSTRACT:"BL2" OR TITLE:"BL2 subtype" OR ABSTRACT:"BL2 subtype" OR TITLE:"Basal-like 2 TNBC" OR ABSTRACT:"Basal-like 2 TNBC" OR TITLE:"Growth-factor signalling subtype of TNBC" OR ABSTRACT:"Growth-factor signalling subtype of TNBC") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Basal-like 2 triple-negative breast cancer (BL2), not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
Immunotherapy can attack hormone-producing glands: most often the thyroid (usually ending in an under-active thyroid needing lifelong tablets), and less often the pituitary (hypophysitis) or adrenal glands, which can be life-threatening if missed.
See all on the product pages:Pembrolizumab·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Basal-like 2 triple-negative breast cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.